ORLANDO,
Fla. and HORSHAM, Pa., Dec. 7, 2015 /PRNewswire/ -- Data from the Phase 3
RAY (MCL3001) study, an investigational clinical trial, showed oral IMBRUVICA®
(ibrutinib) significantly improved progression-free survival (PFS; the primary
endpoint) versus intravenous temsirolimus in patients with relapsed or
refractory mantle cell lymphoma (MCL). Janssen Biotech, Inc. announced
IMBRUVICA was associated with a 57 percent reduction in the risk of disease
progression or death with a median follow-up of 20 months. These data were
published online in The Lancet today and presented in an oral session at
the 2015 American Society of Hematology (ASH) meeting in Orlando, FL. IMBRUVICA
is jointly developed and commercialized by Janssen and Pharmacyclics LLC, an
AbbVie company.